Back

UBLED AF study for safety and efficacy between uninterrupted edoxaban, warfarin and rivaroxaban for AF/Fl ablation patients

23 April 2021 (14:00 - 21:00)
Organised by:
Congress Presentation Part of: ePoster session Arrhythmias EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Narendra Kumar

Bedford Hospital, Bedford (United Kingdom of Great Britain & Northern Ireland)

286 More presentations in this session

Presentation thumbnail
Non-valvular atrial fibrillation recurrence after sinus rhythm restoring at different follow-up periods: phenotype-genotype high-risk groups, considering rs10465885 polymorphism in connexin-40 gene
Doctor T. Mikhalieva (Kyiv, UA)
Abstract Slides
Presentation thumbnail
Atrial fibrillation substrate mapping with decrement evoked potential mapping.
Doctor O. Salvador (Parla, ES)
Abstract Slides
Presentation thumbnail
Atrial tissue characterization by cardiac magnetic resonance and high-density mapping in patients with atrial fibrillation
Miss R. Adelino Recasens (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Proarrhythmic atrial structural and molecular remodeling with advancing age. Implications for post-coronary artery bypass grafting atrial fibrillation occurrence.
Doctor R. SERBAN (Targu Mures, RO)
Abstract Slides
Presentation thumbnail
Find me if you can: lessons learned using the novel cartofinder algorithm in a routine workflow for catheter ablation of atrial fibrillation
Doctor C. Sohns (Bad Oeynhausen, DE)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

EHRA 2021

23 April 2021 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of anticoagulation therapy post atrial fibrillation ablation
9 March 2024
thumbnail
Congress Presentation
Comparative effectiveness of high-density mapping-guided versus empirical linear ablation in left atrial flutter: interim analysis of the FLUTMALINE clinical trial
12 April 2026
thumbnail
Congress Presentation
Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg
1 September 2025
thumbnail
Congress Presentation
Interrupted vs uninterrupted direct oral anticoagulants compared with uninterrupted vitamin K antagonists for atrial fibrillation ablation - A meta-analysis of safety
31 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources